

Psychosis and its relevance to eye care practice

Dr Doina Gherghel

References

1. American Psychiatric Association: Part B: Background information and review of available evidence. IV. Disease definition, natural history and course and epidemiology. In: Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd ed. Arlington: American Psychiatric Association, 2004:40.
2. Levy DL, Holzman PS, Matthysse S, Mendell NR: Eye tracking and schizophrenia: a selective review. *schizophr bull* 1994;20:47-62.
3. Smith D, Pantelis C, McGrath J, Tangas C, Copolov D: Ocular abnormalities in chronic schizophrenia: clinical implications. *Aust N Z J Psychiatry* 1997;31:252-256.
4. Burnham TH: Chlorpromazine. In: Burnham TH ed. *Ophthalmic Drug Facts*. St. Louis: A. Wolter Kluwer Co, 2001:940.
5. Lee MS, Fern AI: Fluphenazine and its toxic maculopathy. *Ophthalmic Res* 2004;36:237-239.
6. Kazuhiko A: Psychiatric symptoms associated with oculogyric crisis: a review of literature for characterization of antipsychotic-induced episodes. *World J Biol Psychiatry* 2006;7:70-74.
7. Bourgeois JA: Ocular side effects of lithium- a review. *J Am Optom Assoc* 1991;62:548-551.
8. Lee MS, Lessell S: Lithium-induced periodic alternating nystagmus. *Neurology* 2003;60:344.
9. Mendhekar DN, Duggal HS: Isolated oculogyric crisis on clozapine discontinuation. *J Neuropsychiatry Clin Neurosci* 2006;18:424-425.
10. Rosenhagen MC, Schmidt U, Winkelmann J, Ebinger M, Knetsch I, Weber F: Olanzapine-induced oculogyric crisis. *J Clin Psychopharmacol* 2006;26:431.
11. Hallgren B: Retinitis pigmentosa combined with congenital deafness with vestibule-cerebellar ataxia and mental abnormality in a proportion of

cases: A clinical and genético-statistical study. *Acta Psychiatr Neurol Scand* 1959;34:5-101.

12. Nuutila A: Dystrophia retinae pigmentosa- dysacusia syndrome (DRD): a study of the Usher's or Hallgren syndrome. *J Tenet Hum* 1978;18:57-88.

13. Waldeck T, Wyszynski B, Medalia A: The relationship between Usher's syndrome and psychosis with Capgras syndrome. *Psychiatry* 2001;64:248-255.

14. Prager S, Jeste DV: Sensory impairment in late-life schizophrenia. *schizophr bull* 1993;19:755-772.

15. Bodensteiner JB, Thompson JN, et al: Volumetric neuroimaging of Usher syndrome: evidence of global involvement. *Am J Med Gen* 1998;79:1-4.

16. International Study Group for Behcet's Disease: Criteria for diagnosis of Behcet's disease. *Lancet* 1990;335:1078-1080.

17. Serdaroglu P: Behcet's disease and the nervous system. *J Neurol* 1998;245:197-205.

18. Evereklioglu C: Current concepts in the etiology and treatment of Behcet's Disease. *Surv Ophthalmol* 2005;50:297-350.

19. Arai T, Mizukami K, Sasaki M, et al: Clinicopathological study on a case of neuro-Behcet's disease: In special reference to MRI, SPECT and neuropathological findings. *Jpn J Psychiatry Neurol* 1994;48:77.

20. Farge EJ, Baer PE, Adams GL, et al: Personality correlates of keratoconus. In: Fann WE ed. *Phenomenology and treatment of Psychophysical Disorders* . Bridgeport, CT: Spectrum Publications, 1982.

21. Giedd KK, Mannis MJ, Mitchell GL, Zadnick K: Personality in keratoconus in a sample of patients derived from the internet. *Cornea* 2005;24:301-307.

22. Rudisch B, D'Orío B, Compton MT: Keratoconus and psychosis. *Am J Psychiatry* 2003;160:5.

23. DeAngelo A, Halliday A. Wernicke-Korsakoff syndrome.

eMedicine: <http://www.emedicine.com/med/topic2405.htm>.

24. Backer JP, Farley JD: Toxic psychosis following atropine eye drops. *BMJ* 1958;6:1390-1392.

25. Khurana AK, Ahluwalia BK, Rajan K, Vohra AK: Acute psychosis associated with topical cyclopentolate hydrochloride. *Am J Ophthalmol* 1988;105:91.

26. Mirshashi A, Kohnen T: Acute psychotic reaction caused by topical cyclopentolate use for cycloplegic refraction before refractive surgery. *Journal Cataract Refract Surg* 2003;29:1026-1030.

27. Epstein E, Kaufman I: Systemic pilocarpine toxicity from overdose in treatment of an attack of angle closure. *Am J Ophthalmol* 1965;59:109-110.

28. Sirois FJ: Pilocarpine psychosis. *Psychosomatics* 2005;46:88.

29. Tripathi A, Chen SI, O'Sullivan S: Acute psychosis following the use of topical ciprofloxacin. *Arch Ophthalmol* 2002;12-:665-666.

30. Bishop AG, Tallon JM: Anticholinergic visual hallucinosis from atropine eye drops. *CJEM* 1999;1.

31. Steinert J, Pugh CR: Two patients with schizophrenic-like psychosis after treatment with beta-blockers. *BMJ* 1979;24:790.

32. McMahon CD, Shaffer RN, Hoskins HD, et al: Adverse effects experienced by patients taking timolol. *Am J Ophthalmol* 1979;88:736.

33. Shore JH, Fraunfelder FT, Meyer SM: Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker. *J Clin Psychopharmacol* 1987;7:264-267.

34. Abramowicz M: Drugs that cause psychiatric symptoms. *Med Lett Drugs Ther* 1989;31:1133.

35. Bron AJ, Chidlow G, Melena J, Osborne NN: Beta-Blockers in the Treatment of Glaucoma. In: Orgul S, Flammer J eds. *Pharmacotherapy in Glaucoma*. Bern: Hans Huber, 2000:79-113.

36. Reinhart WH: Corticosteroid therapy. Schweiz Rundsch Med Prax 2005;16:239-243.

37. Stewart KL. Psychotic patients. A practical approach to evaluation and treatment. An Overview of the objectives in the psychosis module of the OUCOM Psychiatry Block.